References
- C.A.AriasG.A.ContrerasB.E.MurrayManagement of multidrug-resistant enterococcal infectionsClin Microbiol Infect162010555562
- D.MilatovicF.J.SchmitzJ.VerhoefA.C.FluitActivities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European Clinical Bacterial IsolatesAntimicrob Agents Chemother472003400404
- N.BourdonM.Fines-GuyonJ.M.ThioletS.MaugatB.CoignardR.LeclercqChanging trends in vancomycin-resistant enterococci in French hospitals, 2001–08J Antimicrob Chemother662011713721
- C.L.ZhaoH.SunH.WangY.LiuB.HuY.YuAntimicrobial surveillance antimicrobial resistance trends among 5608 clinical gram-positive isolates in China: results from the gram-positive cocci resistance surveillance program (2005–2010)Diagn Microbiol Infect Dis7322012174181
- G.E.SteinW.A.CraigTigecycline: a critical analysisClin Infec Dis432006518524
- CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute. Twenty-Second Informational Supplement. vol. 32, no. 3; 2012.
- S.Dutka-MalenS.EversP.CourvalinDetection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCRJ Clin Microbiol3319952427
- European committee on antimicrobial susceptibility testing. (EUCAST) Breakpoint tables for interpretation of MIC’s and zone diameters. version 3.1 valid from 2013-02-11.
- CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute. Twenty-Second Informational Supplement. vol. 32, no. 2; 2012.
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s026s031lbl.pdf.
- G.KronvallI.KarlssonM.WalderM.SörbergL.E.NilssonEpidemiological MIC cut-off values for tigecycline calculated from Etest MIC valuesusing normalized resistance interpretationJ Antimicrob Chemother5732006498505
- V.SeputieneJ.PovilonisJ.ArmalyteK.SuziedelisA.PavilonisE.SuziedelieneTigecycline – how powerful is it in the fight against antibiotic-resistant bacteria?Medicina (Kaunas)4642010240248
- G.A.PankeyD.S.AshcraftIn vitro antibacterial activity of tigecycline against resistant gram-negative bacilli and enterococci by time-kill assayDiagn Microbiol Infect Dis6432009300304
- Y.H.ChenP.L.LuC.H.HuangC.H.LiaoC.T.LuY.C.ChuangTrends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the tigecycline in vitro surveillance in Taiwan study, 2006 to 2010Antimicrob Agent Chemother563201214521457
- R.HopeS.MushtaqD.JamesT.PllanaM.WarnerD.M.LivermoreTigecycline susceptibility testing group. Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UKJ Antimicrob Chemother65201026022609
- J.W.LiuW.C.KoC.H.HuangC.H.LiaoC.T.LuY.C.ChuangAgreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth micro dilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010Antimicrob Agents Chemother563201214141417
- Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 2nd ed. NCCLS document M23–A2. NCCLS, Wayne, Pa; 2001.